The microbial world has been a rich source of medicines, but our ability to explore the full potential of the microbes both in us and around us has been limited by technology and the difficulty of culturing most microbes in a lab. Biosortia Microbiomics has developed a platform for finding, amplifying, and screening microbes as a potential source of novel, small molecule drugs. We spoke to Ross Youngs, CEO and founder of Biosortia, about the case for exploring various microbiomes to discover new small molecule drugs, how the company’s platform technology enables it to investigate a much broader range of microbes, and its business model for capitalizing on the discoveries it makes.
Engineering Off-the-Shelf Cell Therapies to Target Solid Tumors
Democratizing Drug Discovery
Scaling Genetic Counseling Services with AI
Programming Cell Therapies to Overcome Solid Tumor Defense Systems
Using Liquid Biopsies to Diagnose Infectious Diseases
Striking Hepatitis B at Its Core
Modulating Serotonin with Psychedelics to Treat Neuropsychiatric Conditions
A Procedural Therapy Seeks to Address Type 2 Diabetes at Its Root Cause
Building a Better Path to Neurotherapeutics
Taking a Portfolio Approach to Immuno-Oncology
Engineering Life to Reach New Worlds
Targeting Cancer Drug Side Effects at Their Source
Mapping the Universe of Human Proteins
Fighting Disease by Modulating the Translation of Proteins
Fixing Biopharma’s R&D Productivity by Taking a Cue from the Tech Industry
An Affordable and Widely Available Drug Offers Global Hope against COVID
A Gene Therapy to Program the Body to Produce a Treatment for Osteoarthritis
A Test for Data-Driven Drug Development
Bridging the Gulf Between the Promise and Reality of Precision Health
Using Synthetic Biology to Craft One-Time, Programmable mRNA Therapeutics
Create your
podcast in
minutes
It is Free
DNA Today: A Genetics Podcast
Short Wave
Stuff To Blow Your Mind
Unexplainable
All In The Mind